drugset
drugset / Trial / NCT02509039

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

NCT02509039 ↗

Phase 1 Terminated 15 enrolled Celgene Corporation
NaSingle-groupOpen-labelTreatment

Summary

To determine the safety and tolerability of CC-122 when administered orally to adult Japanese subjects with advanced solid tumors or Non-Hodgkin's Lymphoma (NHL) and to define the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Timeline

Start
2015-09-02
Primary completion
2023-05-09
Completion
2023-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Avadomide Other / unclassified 2 mg Oral

Indications

non-Hodgkin lymphoma